Results 61 to 70 of about 2,545 (184)

The role of artificial intelligence in pharmacy: Revolutionizing drug development and beyond

open access: yesJournal of Intelligent Medicine, Volume 2, Issue 1, Page 27-43, March 2025.
This comprehensive review explores the integration of artificial intelligence (AI) in the field of pharmacy, covering advancements in drug discovery, personalized medicine, medication management, and patient care. It synthesizes current research, methodologies, and future prospects, offering insights into how AI technologies are reshaping ...
Usman Shettima Usman   +8 more
wiley   +1 more source

Comparative effectiveness of different chemotherapy regimens of advanced-stage Hodgkin lymphoma in adults: a network meta-analysis

open access: yesCancer Management and Research, 2018
Tingting Zhang,1 Yan Yao,2 Fubin Feng,3 Wenge Zhao,2 Jinhui Tian,4 Chao Zhou,3 Xue Wang,5 Shengjie Dong,6 Jia Li,2 Lingyu Qi,7 Changgang Sun3,8 1College of Traditional Chinese Medicine, Shandong University of Traditional Chinese Medicine, Jinan, Shandong
Zhang T   +10 more
doaj  

Optimizing treatment efficacy and fertility preservation in patients undergoing hematopoietic stem cell transplantation: A narrative review of ovarian shielding with total‐body irradiation or treosulfan‐based conditioning regimens

open access: yesReproductive Medicine and Biology, Volume 24, Issue 1, January/December 2025.
Abstract Background Pediatric and adolescent/young adult (AYA) patients with hematologic malignancies often require hematopoietic stem cell transplantation (HSCT) using conditioning regimens that pose high risks for gonadal toxicity. Traditional protocols, including total body irradiation (TBI) and busulfan‐based regimens, can impair fertility.
Yuji Tanaka   +7 more
wiley   +1 more source

Risk‐Stratified and Response‐Adapted Therapy for Pediatric Hodgkin Lymphoma in Argentina: The GATLA Experience

open access: yesAdvances in Hematology, Volume 2025, Issue 1, 2025.
Background: The international cooperation between GATLA and AHOPCA with the support of St. Jude led to the adoption of the OEPA/COPDAC as a strategy to improve outcomes in high risk (HR) patients with HL. This study also includes the ABVD regimen for intermediate risk (IR) and low risk (LR) patients. Methods: Patients were stratified by predefined risk
David Veron   +11 more
wiley   +1 more source

Influence of cysteine on mechlorethamine - induced chromosomal aberrations in cultured human lymphocytes

open access: yes, 1995
The aim of the present paper was to find out by in vitro chromosomal aberration test using human lymphocytes whether cysteine has anticlastogenic properties towards a well-known mutagen - mechlorethamine.
Blaszczyk, A
core  

A Rare Case of Hodgkin Lymphoma With Isolated Epitrochlear Lymphadenopathy. Our Experience and Main Differential Diagnosis

open access: yesCase Reports in Medicine, Volume 2025, Issue 1, 2025.
Hodgkin lymphoma (HL) is a type of lymphoma, characterized by the presence of abnormal Reed‐Sternberg cells. It typically affects lymph nodes, generally in the upper body (such as neck, chest, and armpits). It can also involve the spleen, liver, and bone marrow. In the literature, there are sporadic cases of atypical localization of HL. The aim of this
Laura Cea   +9 more
wiley   +1 more source

Predicting Drug Targets in Human Cancers

open access: yesJournal of Clinical Pharmacy and Therapeutics, Volume 2025, Issue 1, 2025.
Introduction A large amount of knowledge has accumulated regarding the pharmacology of most cancer types, including their side effects, and during the last decade, many novel agents have emerged, accompanied by increased costs for healthcare systems. Aim Artificial intelligence (AI) was applied in healthcare services, and the benefit of its use in the ...
David Calderón Guzmán   +7 more
wiley   +1 more source

The Impact of Regularly Used Treatments on Daily Life of Cutaneous T‐Cell and B‐Cell Lymphoma Patients

open access: yes
JEADV Clinical Practice, Volume 4, Issue 2, Page 552-555, June 2025.
Michelle Raaijmakers   +5 more
wiley   +1 more source

Mechlorethamine, vincristine, and procarbazine chemotherapy for recurrent high-grade glioma in adults: a phase II study.

open access: yes, 1990
We undertook a phase II study of combination chemotherapy with mechlorethamine (nitrogen mustard) 6 mg/m2 intravenously day 1 and day 8, vincristine 2 mg intravenously day 1 and day 8, and procarbazine 100 mg/m2 orally days 1 through 14 (MOP) in adults ...
T Coyle   +9 more
core   +1 more source

Mechlorethamine, vincristine, melphalan and prednisolone rescue chemotherapy protocol for resistant feline lymphoma

open access: yes, 2017
Objectives The goals of this retrospective study were to evaluate the use of mechlorethamine, vincristine, melphalan and prednisolone (MOMP) chemotherapy for rescue of feline lymphoma, to describe the protocol’s toxicity and to determine prognostic ...
Olya A Martin, Josh Price
core   +1 more source

Home - About - Disclaimer - Privacy